GBNHF — Greenbrook TMS Share Price
- $2.27m
- $164.33m
- $73.79m
- 20
- 80
- 17
- 33
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.03 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -35.24% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 35.69 | 43.13 | 52.2 | 66.83 | 73.79 | 82.42 | n/a | 28.26% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray), non-invasive therapies for the treatment of Major Depressive Disorder (MDD) and other mental health disorders. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. The Company operates a network of outpatient mental health service centers that specialize in treatment across the United States. It offers Treatment Centers in convenient locations to provide easy access to patients and clinicians. The Company owns and operates 130 Treatment Centers in the Commonwealths of Massachusetts, Virginia and Pennsylvania and the States of Maryland, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, and Michigan.
Directors
- Bill Leonard PRE (56)
- Edwin Cordell CFO
- Roberto Drassinower COO (50)
- Diana Shi SVP
- Euphia Hsu Smith CMO
- Geoffrey Grammer OTH
- Colleen Campbell LED (63)
- Sasha Cucuz DRC (43)
- Robert Higgins DRC
- Elias Vamvakas DRC (62)
- Brian Burke IND (65)
- Adrienne Graves IND
- Adele Okiva IND (55)
- Frank Tworecke IND (74)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- February 9th, 2018
- Public Since
- November 27th, 2018
- No. of Employees
- 629
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 168,635,122

- Address
- 890 Yonge St 7th Floor, TORONTO, M4W 3P4
- Web
- https://www.greenbrooktms.com/
- Phone
- +1 4163229700
- Contact
- Stefan Eftychiou
- Auditors
- KPMG LLP
Upcoming Events for GBNHF
Q1 2025 Greenbrook Tms Inc Earnings Release
Similar to GBNHF
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
ACI Global
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
FAQ
As of Today at 19:55 UTC, shares in Greenbrook TMS are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Greenbrook TMS last closed at $0.01 and the price had moved by -95.36% over the past 365 days. In terms of relative price strength the Greenbrook TMS share price has underperformed the S&P500 Index by -95.97% over the past year.
The overall consensus recommendation for Greenbrook TMS is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGreenbrook TMS does not currently pay a dividend.
Greenbrook TMS does not currently pay a dividend.
Greenbrook TMS does not currently pay a dividend.
To buy shares in Greenbrook TMS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Greenbrook TMS had a market capitalisation of $2.27m.
Here are the trading details for Greenbrook TMS:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GBNHF
Based on an overall assessment of its quality, value and momentum Greenbrook TMS is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Greenbrook TMS is $0.28. That is 1993.72% above the last closing price of $0.01.
Analysts covering Greenbrook TMS currently have a consensus Earnings Per Share (EPS) forecast of -$0.43 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Greenbrook TMS. Over the past six months, its share price has underperformed the S&P500 Index by -85.05%.
As of the last closing price of $0.01, shares in Greenbrook TMS were trading -74.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Greenbrook TMS PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Greenbrook TMS' management team is headed by:
- Bill Leonard - PRE
- Edwin Cordell - CFO
- Roberto Drassinower - COO
- Diana Shi - SVP
- Euphia Hsu Smith - CMO
- Geoffrey Grammer - OTH
- Colleen Campbell - LED
- Sasha Cucuz - DRC
- Robert Higgins - DRC
- Elias Vamvakas - DRC
- Brian Burke - IND
- Adrienne Graves - IND
- Adele Okiva - IND
- Frank Tworecke - IND